Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare ACO Rules For Adopting New Drugs Could Follow D Model – PhRMA

Executive Summary

Medicare accountable care organizations should be required to update their clinical guidelines to incorporate new treatments shortly after they are launched, the Pharmaceutical Research and Manufacturers of America suggests in June 6 comments to the Centers for Medicare and Medicaid Services.

You may also be interested in...



CMS Interested In Part D Plan Collaboration With Medicare ACOs

In a draft version of its annual instructions to Part D plans, CMS says it is seeking feedback from Part D sponsors and other stakeholders on “possible strategies for achieving better coordination” between stand-alone Medicare Part D plans and accountable care organizations to improve pharmacy care.

Final Medicare ACO Rule Rejects Pharma Industry Requests For Rx Access Protections

Final rule on Medicare accountable care organizations created under the Affordable Care Act is released Oct. 20.

Medicare ACO Cost Incentives For Part B-To-D Rx Shifts Worry Stakeholders

CMS should look for ways to ensure that financial incentives for Medicare accountable care organizations do not promote inappropriate shifts in prescribing from the Part B benefit to Part D, biotech and clinician groups urge in comments filed with the agency June 6.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel